Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease affecting a quarter of the global population and is often associated with adverse health outcomes. The increasing prevalence of MAFLD occurs in parallel to that of metabolic syndrome (MetS), which in fact plays a major role in driving the perturbations of cardiometabolic homeostasis. However, the mechanisms underpinning the pathogenesis of MAFLD are incompletely understood. Compelling evidence from animal and human studies suggest that heightened activation of the sympathetic nervous system is a key contributor to the development of MAFLD. Indeed, common treatment strategies for metabolic diseases such as diet and exercise to induce weight loss have been shown to exert their beneficial effects at least in part through the associated sympathetic inhibition. Furthermore, pharmacological and device-based approaches to reduce sympathetic activation have been demonstrated to improve the metabolic alterations frequently present in patients with obesity, MetSand diabetes. Currently available evidence, while still limited, suggests that sympathetic activation is of specific relevance in the pathogenesis of MAFLD and consequentially may offer an attractive therapeutic target to attenuate the adverse outcomes associated with MAFLD.

Download Full-text

The beneficial effects of taurine in alleviating fatty liver disease

Journal of Functional Foods ◽

10.1016/j.jff.2020.104351 ◽

2021 ◽

Vol 77 ◽

pp. 104351

Author(s):

Qi Song ◽

Junxia Guo ◽

Yanzhen Zhang ◽

Wen Chen

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Beneficial Effects

Download Full-text

Non-alcoholic fatty liver disease and beneficial effects of dietary supplements

World Journal of Hepatology ◽

10.4254/wjh.v7.i12.1723 ◽

2015 ◽

Vol 7 (12) ◽

pp. 1723 ◽

Cited By ~ 3

Author(s):

Ludovico Abenavoli

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Dietary Supplements ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Beneficial Effects ◽

Alcoholic Fatty Liver Disease

Download Full-text

Reply to: “Might some of the beneficial effects of the Mediterranean diet on non-alcoholic fatty liver disease be mediated by reduced iron stores?”

Journal of Hepatology ◽

10.1016/j.jhep.2013.05.022 ◽

2013 ◽

Vol 59 (3) ◽

pp. 640 ◽

Cited By ~ 1

Author(s):

Marno C. Ryan ◽

Paul Desmond ◽

Andrew Wilson

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Mediterranean Diet ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Iron Stores ◽

Beneficial Effects ◽

The Mediterranean ◽

Alcoholic Fatty Liver Disease

Download Full-text

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease

Digestive Diseases ◽

10.1159/000491429 ◽

2018 ◽

Vol 37 (1) ◽

pp. 63-68 ◽

Cited By ~ 8

Author(s):

Roger F. Butterworth ◽

Ali Canbay

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Preliminary Report ◽

Liver Enzymes ◽

Hepatic Microcirculation ◽

Alcoholic Fatty Liver ◽

Beneficial Effects ◽

Anti Oxidant ◽

Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited. Summary: L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6–9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with non-alcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties. Key Messages: (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA’s ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.

Download Full-text

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies

Journal of Clinical Medicine ◽

10.3390/jcm10173783 ◽

2021 ◽

Vol 10 (17) ◽

pp. 3783

Author(s):

Julie Steen Pedersen ◽

Marte Opseth Rygg ◽

Reza Rafiolsadat Serizawa ◽

Viggo Bjerregaard Kristiansen ◽

Nicolai J. Wewer Albrechtsen ◽

...

Keyword(s):

Gastric Bypass ◽

Sleeve Gastrectomy ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Liver Steatosis ◽

Plasma Lipid ◽

Alcoholic Fatty Liver ◽

Beneficial Effects ◽

Alcoholic Fatty Liver Disease

Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histological assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Consequently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p < 0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.

Download Full-text